Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT07161453Phase 4Not yet recruiting
Phase 4, open-label trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (4 arms), sponsored by Liaoning Medical Center. Primary endpoint: Disease-Free Survival at 2 years. Planned start Sep 2025; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT07161453.